Kornimate/medical-research-clean huggingface dataset:
effect of lifestyle factors and hormone function on breast density in healthy hispanic women who are undergoing mammography for breast cancer screening

Conditions: Breast Cancer

Summary: rationale: lifestyle factors, such as physical activity, diet, and obesity, and hormone function may affect breast density. screening tests, such as mammography, may help doctors find tumor cells early and plan better treatment for breast cancer. purpose: this clinical trial is studying the effect of lifestyle factors and hormone function on breast density in healthy hispanic women who are undergoing mammography for breast cancer screening.

objectives: * correlate physical activity, diet, and obesity, as measured by body mass index and waist circumference, with percent breast density and the absolute estimate of total dense breast area in healthy hispanic women undergoing screening mammography. * correlate fasting serum insulin growth factor (igf)-1 and the molar ratio of igf-1 to igf binding protein-3 with breast density in participants undergoing screening mammography. * correlate insulin concentration and insulin resistance with breast density in participants undergoing screening mammography. outline: this is a multicenter study. participants undergo blood collection and physical examination. participants also complete breast cancer risk factor, food frequency, and physical activity questionnaires and receive breast health and physical activity education. participants then undergo a digital screening mammogram. participants are notified of mammogram results. projected accrual: a total of 114 participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * healthy hispanic women * registered patient at the erie family health centers' west town or humboldt park clinics * no screening mammography within the past 12 months * no abnormality on clinical breast exam * no history of breast cancer * hormone receptor status: * not specified patient characteristics: age * 40 and over sex * female menopausal status * not specified performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * not pregnant prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: breast cancer
a trial to evaluate a multivalent pneumococcal conjugate vaccine in healthy adults 50-85 years of age

Conditions: Pneumococcal Infections

Summary: this is a 2-stage, phase 1/2, randomized, active-controlled, observer-blinded study with a 2-arm parallel design in each stage. in stage 1 healthy adults 50 to 64 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single intramuscular dose of multivalent pneumococcal conjugate vaccine or a licensed tetanus, diphtheria, acellular pertussis combination vaccine (tdap) (control group). in stage 2 healthy adults 65 to 85 years of age previously vaccinated with prevnar 13 \>=2 months prior to investigational product administration will be randomized equally to receive either a single intramuscular dose of multivalent pneumococcal conjugate vaccine or the licensed 23-valent pneumococcal polysaccharide vaccine (control group).


Eligibility criteria:
inclusion criteria: * stage 1: healthy male or female adults 50 to 64 years of age with no history of pneumococcal vaccination * stage 2: healthy male or female adults 65 to 85 years of age previously vaccinated with prevnar 13 \>= 2 months prior to investigational product administration exclusion criteria: * stage 1: vaccination within 12 months before investigational product administration with diphtheria-, pertussis-, or tetanus-containing vaccine * stage 2: previous vaccination with any pneumococcal vaccine other than a single prior dose of prevnar 13
comparative results after dsaek, ut-dsaek and dmek for fuchs endothelial corneal dystophy

Conditions: Corneal Dystrophy

Summary: purpose of the research is to describe and compare the evolution of bscva after dmek, dsaek and ut-dsaek for fuchs endothelial corneal dystrophy (fecd) and moderate pseudophakic bullous keratopathy (pbk). to secondarily research the correlates criterions with best spectacle corrected visual acuity (bscva) 12 months postoperatively.

the purpose of the research is to describe and compare the evolution of bscva after dmek, dsaek and ut-dsaek for fuchs endothelial corneal dystrophy (fecd) and moderate pseudophakic bullous keratopathy (pbk). to secondarily research the correlates criterions with best spectacle corrected visual acuity (bscva) 12 months postoperatively. in a retrospective, single-center, observational study, 218 eyes treated with dmek (n=110), ut-dsaek (n=58) and dsaek (n=50) surgeries were studied. patients requiring posterior lamellar transplantation for fecd or moderate pbk, with preoperative bscva of less than 0.3 logmar, were selected. patients with pathologies that may seriously affect va postoperatively were excluded. graft thickness for dsaek was measured during the surgery and in vivo at d8, d15, m1, m6, m12 and m24. the primary endpoint was best spectacle corrected visual acuity (bscva) in logmar at 6, 12 and 24 months. we deliberately differentiated our postoperative visual results by comparing dmek with dsaek or ut-dsaek with central graft thickness (cgt) measurements carried out either pre-operatively (less than or greater than 130 µm) or post-operatively at 6 months (less than or greater than 100µm). type of endothelial graft, donor and recipient's ages, graft's endothelial cell density (ecd), rebubbling rate, preoperative va, graft's indications and surgical time were also tested to explain bscva at 12 months.

Eligibility criteria:
inclusion criteria: * patients requiring posterior lamellar transplantation for fecd or moderate pbk, with preoperative bscva of less than 0.3 logmar, exclusion criteria: * patients with pathologies that may seriously affect va postoperatively

Keywords: dmek, dsaek, ut-dsaek, endothelial cell
study evaluating the efficacy and safety of etanercept in chinese subjects with rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: the objective of this study is to compare in chinese subjects with rheumatoid arthritis (ra) the efficacy and safety in this subject population of 50 mg once-weekly injections of etanercept versus placebo in subjects receiving methotrexate. this is a multi-center, double-blind, randomized, parallel and placebo-controlled outpatient study. approximately 150 subjects will participate in this study for about 18 weeks including a screening period up to 4 weeks, 12-week treatment period, and a 2-week follow-up period at approximately 25 sites.


Eligibility criteria:
inclusion criteria: * must be of chinese ancestry and living in china. * meets the american rheumatism association 1987 revised criteria for the classification of ra. * have active ra at the time of study enrollment (before the start of the screening period,) as demonstrated by 5 swollen and 5 tender/painful joints. exclusion criteria: * previous receipt of etanercept; antibody to tumor necrosis factor (tnf) antibody (infliximab, adalimumab), anti-cd4 antibody or diphtheria il-2 fusion protein (dab il-2).

Keywords: arthritis chinese
a survey on the cognition and use of intraosseous access among medical staff

Conditions: Intraosseous Access

Summary: a survey on the cognition and use of intraosseous access among emergency medical staff, which is based on the platform of "wjx.cn", from january 5, 2018 to january 23, 2018, via local emergency-related academic organizations to emergency medical staff throughout the country. there are 3 sections in the questionnaire: the demographic information of the participants; cognition levels and clinical use of io; barriers and attitudes towards clinical use of io including willingness, confidence and training demand.

this research is a cross-sectional survey research, using the method of network survey, with domestic emergency medicine medical staff as the research object. inclusion criteria: 1) emergency medical staff who have a chinese medical practitioner certificate or a nurse practitioner certificate and are within the valid registration period; 2) agree to participate in this study. exclusion criteria: incomplete questionnaires. the questionnaire was designed for the "survey of current status of marrow cavity pathway cognition of medical staff in emergency department", including three parts: (1) general information of the survey object; (2) cognition and use status of io; (3) clinical application of io attitude. based on the "questionnaire star" platform, questionnaires are distributed through various emergency-related academic organizations. the front page of the questionnaire clearly marked the reminder of voluntary participation in the survey and related declarations, and it could be filled out after informed consent.

Eligibility criteria:
inclusion criteria: 1) emergency medical staff who have a chinese medical practitioner certificate or a nurse practitioner certificate and are within the valid registration period; 2) agree to participate in this study. exclusion criteria: incomplete questionnaires.
prophesys 1: an observational study on predictors of response in treatment-naïve patients with chronic hepatitis c virus (hcv)treated with pegasys (peginterferon alfa-2a)

Conditions: Hepatitis C, Chronic

Summary: this observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis c initiated on treatment with pegasys (peginterferon alfa-2a) and ribavirin. data will be collected during the treatment period (24 or 48 weeks) and 12 and 24 weeks after the end of treatment. target sample size is \<5000.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * chronic hepatitis c * informed consent to data collection exclusion criteria: * co-infection with hiv or hepatitis b virus (hbv) * previous treatment with peginterferon and/or ribavirin
neoscb app for screening jaundice in newborns

Conditions: Neonatal Jaundice

Summary: about 60% of babies born after 36 weeks of pregnancy have jaundice during the first two weeks of life. due to the accumulation of bilirubin in the bloodstream, jaundiced babies appear yellow, which allows healthcare professionals to visually identify significantly jaundiced babies. they will be referred for a blood test to determine if the bilirubin level is so high that treatment such as phototherapy, or more intensive help is required. left untreated or treatment delayed, jaundice can potentially result in serious brain damage and even death (rare). however, visual inspection of jaundiced babies is inaccurate, often need to unnecessary referrals to hospital blood tests. we have developed the "neoscb" smartphone app, which accurately detects significant jaundice by taking photographs of the baby's sclera (white part of an eye) and analysing its yellowness using a diagnostic algorithm. the neoscb app has previously been validated in ghana involving over 700 newborn babies. in this new study, we will recruit 405 newborn babies with a range of jaundice levels to validate an optimised diagnostic algorithm following our latest research. two existing commercial screening devices will also be used to investigate whether the app delivers a similar accuracy, at a fraction of the cost. we will enhance the usability of the app and add new features following feedback from patients and healthcare professionals. a health economic study will be conducted to evaluate the economic benefits to the nhs.


Eligibility criteria:
inclusion criteria: * term newborn babies with and without jaundice (postnatal age 0 day to 28 days) exclusion criteria: * newborn babies who are clinically unwell and require urgent medical attention, and babies who have received phototherapy recently

Keywords: screening newborn babies mobile app neonatal jaundice
study in patients with relapsed/refractory primary mediastinal lymphoma treated with pembrolizumab or nivolumab in combination with brentuximab vedotin in a real-life context

Conditions: Primary Mediastinal B Cell Lymphoma

Summary: observational, non-interventional, retrospective, multicenter study focusing on the efficacy and safety of pembrolizumab monotherapy and nivolumab in combination with brentuximab vedotin in clinical practice patients with primary mediastinal b cell lymphoma relapsed/refractory

observational, non-interventional, retrospective, multicentre study focusing on the efficacy and safety of pembrolizumab as monotherapy and nivolumab in combination with brentuximab vedotin in daily clinical practice in patients with primary mediastinal b cell lymphoma relapsed/refractory. the study aims to retrospectively evaluate the efficacy in terms of overall response rate (orr, sum of complete response rate \[cr\] and partial response rate \[pr\]) of pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in patients with primary mediastinal b cell lymphoma relapsed/refractoryl treated in a real-life setting from november 2020 until november 2021. secondary objectives * to assess efficacy, in terms of: * duration of response (dor) * progression-free survival (pfs) * overall survival (os) * disease-free survival (dfs) * best response rate (achieved at any time during treatment) * to evaluate the safety and tolerability of pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin the study will include patients with primary mediastinal b cell lymphoma relapsed/refractory treated with pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a real-life setting from november 2020 until november 2021.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of primary mediastinal b cell lymphoma relapsed/refractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a real-life context with till novembre 2021 2. age ≥ 18 years at enrollment 3. signature of written informed consent (where applicable) exclusion criteria: 1. primary mediastinal b cell lymphoma relapsed/refractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a clinical trial context.

Keywords: pembrolizumab nivolumab brentuximab vedotin
trans-aortic valve replacement and renal infarction

Conditions: Renal Infarction

Summary: kidney magnetic resonance assessment before and after undergoing transcatheter aortic valve replacement

each patient will undergo magnetic resonance assessment of the kidneys before the tavr. on the third to 7th day after the atvr, a second mri to the kidneys will be performed. we will assess the changes and new lesions between both mri tests and will perform a qualitative and quantitative measurement.

Eligibility criteria:
inclusion criteria: * severe symptomatic aortic stenosis * patient is able to lay down supine for 20 min (the time needed to perform the mri) without any difficulties. exclusion criteria: * patient is on chronic renal replacement therapy (dialysis) * documented thrombus in the left ventricle or left atria
web-based study for cancer survivors

Conditions: Physical Activity; Dietary Modification

Summary: in this parallel group study, participants were randomized to either 1 of 3 conditions (a) fruit and vegetable consumption, (b) dietary fat and added sugars, or (c) physical activity.

in this study, the investigators will evaluate the feasibility and preliminary results of a 3-month web-based lifestyle intervention 500 female cancer survivors. specific aim 1: to determine the rates of recruitment, retention, attendance, satisfaction, adverse events, and barriers to participation in the proposed intervention. specific aim 2: to determine whether a home-based intervention is associated with greater improvements in mean minutes of moderate to vigorous physical activity, diet quality, body size, constructs of social cognitive theory, and health-related quality of life than participants randomized to a sedentary behavior reduction condition.

Eligibility criteria:
inclusion criteria: * previously diagnosed with breast cancer; * 18-80 years old at time of cancer diagnosis; * english-speaking; * have access to high-speed internet. exclusion criteria: * be currently enrolled in another intervention study or recently completed a study promoting healthy lifestyle behaviors (diet and/or exercise). * participants answering 'yes' to one or more of the questions on the physical activity readiness questionnaire (par-q) will need to obtain approval from a physician before they can participate in the intervention. * pregnant women will be excluded from the protocol.

Keywords: breast cancer cancer survivorship dietary intake physical activity quality of life
metabolism and pharmacokinetics of primaquine enantiomers in human volunteers receiving a seven day dose regimen

Conditions: Malaria; Glucose 6 Phosphate Dehydrogenase Deficiency

Summary: to investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of pq in healthy human volunteers, receiving study drug over the course of 7 days.

the primary objective of this project is to investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of pq in healthy human volunteers. based on the results of this study, if one enantiomer seems to show a better safety profile (in terms of hematological effects), an analogous study will be carried out in g6pd deficient individuals (under a separate protocol). the studies are primarily aimed at understanding the tolerability and safety of the enantiomers in g6pd deficiency. if one shows a better safety profile, ultimately the evaluation of its efficacy will be required.

Eligibility criteria:
inclusion criteria: * normal, healthy adults aged 18 to 65 years exclusion criteria: * known history of liver, kidney or hematological disease * known history of cardiac disease, non sinus rhythm arrhythmia or qt prolongation * autoimmune disorders * report of an active infection * evidence of g6pd deficiency * participant is pregnant or breast-feeding, or is expecting to conceive during the study.

Keywords: hemolysis primaquine pharmacokinetics
efficacy of an antibacterial toothpaste and patients' satisfaction

Conditions: Caries; Gingivitis

Summary: the primary objective of this randomized controlled clinical trial (rcct) will be to compare the efficacy in reducing the quantity of streptococcus mutans (s. mutans) in saliva of a recently introduced toothpaste compared to a commercially available toothpaste. the secondary outcomes will be to assess patients' impression of the toothpastes (in terms of taste, satisfaction etc.), and to investigate potential changes in dentin hypersensitivity, plaque formation and gingival inflammation.


Eligibility criteria:
inclusion criteria: 1. patients with minimum 20 teeth; 2. good oral hygiene level (gingival bleeding index not exceeding 20%) 3. patients willing to participate in the study and able to sign an informed consent exclusion criteria: 1. tooth anomalies (amelogenesis imperfecta, dentinogenesis imperfecta etc.); 2. intrinsic stain (fluorosis); 3. caries lesions; 4. advanced periodontal disease (probing \>2, spontaneous gum bleeding, tooth mobility \>1); 5. smokers; 6. use of orthodontic devices; 7. use of antibiotics in the last 3 months; 8. use of antibacterial mouth rinses in the last 3 months; 9. potential allergies; 10. drug and alcohol abuse;
snooze control: sleep duration & glucose metabolism

Conditions: Glucose Metabolism Disorders

Summary: this project investigated how glucose metabolism differs due to sleep deprivation for three consecutive nights as compared to sufficient sleep for three nights by examining concentrations of glucose, insulin, and other factors involved in glucose metabolism.

16 participants were enrolled in the study (8 females, 8 males) aged 18-25 years. in order for the participants to qualify for the study, each had to wear a pedometer for a week before the study began to determine eligibility. each participant came to the lab for an oral glucose tolerance test on a morning, following three nights when they were sleep deprived, and on another morning when they had three nights' sufficient sleep. the sequence of the oral glucose tolerance tests were randomly assigned. the sleep duration for participants was monitored by the readings of the sleep monitors that each participant wore. the oral glucose tolerance tests were performed after an overnight fast. a 20-gauge polyethylene catheter was placed in the antecubital vein for blood sampling. blood samples were drawn once (0 min) before and 4 times (30, 60, 90, and 120 min) after a 75g glucose drink was consumed for the determination of plasma glucose, insulin, and concentrations of other factors. each participant was told to continue their regular routine during the study period, including diet, caffeine usage, and exercise.

Eligibility criteria:
inclusion criteria: * healthy college-aged males and females * being minimally active exclusion criteria: * average more than 15,000 steps a day * major health issues such as heart disease, diabetes * taking medication to help with sleep or using a sleeping device * any type of sleep problem such as sleep apnea

Keywords: glucose metabolism sleep deprivation
postoperative pulmonary complications in obstructive sleep apnea patients

Conditions: Obstructive Sleep Apnea; Postoperative Complications

Summary: it is known that perioperative respiratory complications occur more often in obstructive sleep apnea syndrome (osas) patients during general anesthesia. although there are prospective rcts in this area, the need for further and larger studies remains due to the heterogenity of the results. moreover, the incidence of postoperative pulmonary complications in osas patients undergoing surgery in turkey and the predictive factors affecting the respiratory adverse events are uncertain. therefore, in this prospective observational cohort study, it was aimed to determine the incidence of postoperative pulmonary complications and the predictor factors associated with patient, anesthesia and surgery in surgical patients with a confirmed or highly suspected osas diagnosis undergoing general anesthesia.


Eligibility criteria:
inclusion criteria: 1. age: 18-65 years 2. asa physical status i-iii 3. preoperative osas diagnosis (with polysomnography or stop-bang questionnaire score) 4. surgeries performed under general anesthesia 5. endotracheal intubation facilitated by neuromuscular blockers exclusion criteria: 1. asa physical status iv or v 2. planned admission to the icu after surgery 3. cardiac surgery 4. non-operating room anesthesia 5. neuromuscular disease 6. emergency or re-operational procedure 7. laryngectomy 8. pneumonectomy 9. invasive airway access 10. pregnancy 11. outpatient surgery

Keywords: obstructive sleep apnea postoperative pulmonary complications general anesthesia